CTOs on the Move

BioTheryX

www.biotheryx.com

 
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioTheryX raised $92M on 05/20/2021

Similar Companies

TMRW Life Sciences

Founded in 2018, TMRW Life Sciences provides the first and only automated, robotic, software-guided specimen management solution for the safe management of frozen eggs and embryos central to the IVF process.

Sanford Jackson Medical Center

Sanford Jackson Medical Center is a Jackson, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metavention

Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.

Omeros Corporation

Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

X-Vax Technology

We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.